Antibiotics passe, time for new superbug killers - The Times of India.
Bangalore-based GangaGen Biotechnologies has developed a phage-based genetically modified protein, StaphTAME. The protein, set to undergo clinical trials, can prevent and treat Staphlylococcal infections, including MRSA, claims the firm. StaphTAME kills all strains of Staph including the superbug MRSA. The product has completed all preclinical development, says Ram Ramachandran, chairman of GangaGen Biotechnologies. A more recent creation, anti-microbial nano-particles are polymers and peptides that destroy bacterial cell walls. These can be synthesized at low cost and in large quantities and have efficiency comparable to conventional anti-microbial agents.
